{"domain":"rare-disease-atlas.github.io","count":1,"changes":[{"captured_at":"2026-11-22T14:39:59.774230","card_hash":"7491a492b0b9e128db5f1195e513ae98a6f7ccd7798a1bd5e7ca3ac3c922ddbf","previous_card_hash":null,"diff":{"skills_added":[{"id":"autoimmune-myelofibrosis-iron-triage","name":"Reversible Autoimmune Myelofibrosis (AIMF) & Dual Iron Overload Positive-Control Triage","description":"Contrasts clonal JAK2+ PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (AIMF: 74-80% hematologic & marrow fibrosis remission on corticosteroids/rituximab) and dual transfusional + IL-6/hepcidin/ferroportin reticuloendothelial iron overload.","tags":["autoimmune-myelofibrosis","AIMF","lupus","SLE","hepcidin","ferroportin","iron-overload","fibrosis-reversal"],"inputModes":null,"outputModes":null},{"id":"federated-7000-orphan-disease-scan","name":"Live 7,000-Orphan-Disease Federated Diligence Scan","description":"Queries OpenTargets Platform v4, ClinicalTrials.gov v2, and PubMed live via search_any_orphan_indication for any of 7,000+ orphan diseases, pairing FY2026 FDA Orphan Drug ($4,682,003 PDUFA waiver, 7-yr exclusivity) and Rare Pediatric PRV unit economics against Paired Myelofibrosis Flagships.","tags":["orphan-drug","7000-diseases","OpenTargets","ClinicalTrials","PubMed","PRV","diligence"],"inputModes":null,"outputModes":null},{"id":"jak2-clonal-myelofibrosis-diligence","name":"Clonal JAK2 V617F+ Myelofibrosis (JH2 vs JH1) Translational Diligence","description":"Analyzes Type I JH1 JAK inhibitor cytopenia & persistence failure modes, mutant-selective JH2 pseudokinase binders/degraders (INCB160058 NCT06313593, PDB 4FVR/6E2Q/8BAK vs WT 4FVP), Type II persistence breakers (AJ1-11095 NCT06343805), mutant CALR biologics, and single-cell bone marrow datasets (GSE144568, GSE122198).","tags":["myelofibrosis","JAK2-V617F","JH2","JH1","CALR","PROTAC","clinical-trials"],"inputModes":null,"outputModes":null},{"id":"non-dilutive-grant-stacking","name":"Orphan Disease Non-Dilutive Capital & Ethical Community Validation","description":"Lists stackable NIH SBIR/STTR, ARPA-H, MPN Research Foundation, Blood Cancer United TAP, CDCN/Every Cure, and FDA OOPD grants (list_non_dilutive_grants) paired with non-extractive patient-community validation pathways (get_validation_communities).","tags":["grants","SBIR","ARPA-H","non-dilutive","patient-advocacy","ethical-validation"],"inputModes":null,"outputModes":null},{"id":"query-myelofibrosis-molecular-apis","name":"Query Myelofibrosis Molecular, Structural, Comparison & Catalyst Micro-APIs","description":"Queries zero-auth micro-APIs for single-cell & stromal gene signatures (GET /api/gene?symbol=&cohort=&compartment=&q=), JAK2 V617F JH2 vs WT structural pockets (GET /api/pocket?pdb=&domain=&target=&q=), side-by-side Paired Flagship comparisons (GET /api/compare?a=jak2-myelofibrosis&b=autoimmune-myelofibrosis), and upcoming clinical/regulatory catalysts (GET /feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).","tags":["molecular-api","gene-signatures","structural-pockets","compare","catalysts","ics-calendar","JAK2-V617F","AIMF"],"inputModes":null,"outputModes":null},{"id":"search-orphan-venture-wedges","name":"Search Orphan Disease Startup Blueprints & 90-Day Validation Plans","description":"Searches concrete rare-disease startup wedges via search_founder_opportunities and generates 30/60/90-day killer-experiment roadmaps via get_90_day_validation_plan across AI/ML drug repurposing, public-health/EHR diagnostics, and venture-philanthropy spinouts.","tags":["rare-disease","venture","biotech","ai-bio","public-health","90-day-plan"],"inputModes":null,"outputModes":null},{"id":"stress-test-orphan-hypothesis","name":"Stateless Orphan Hypothesis Red-Team & Biological/Venture Stress-Test","description":"Red-teams candidate drug targets, structural ML binders, diagnostic triage classifiers, or orphan venture theses via POST https://api.rare-disease-atlas.workers.dev/api/stress-test against JH2 vs JH1 selectivity traps, AIMF vs Triple-Negative PMF pathology discordance, Phase 3 endpoint casualties (TRANSFORM-1, IMpactMF), MyelofibrosisBench-v1, and FY2026 FDA Orphan unit economics.","tags":["stress-test","red-team","hypothesis-validation","myelofibrosis","AIMF","JAK2-V617F","MyelofibrosisBench-v1"],"inputModes":null,"outputModes":null},{"id":"submit-research-finding-or-benchmark","name":"Two-Way A2A Research Finding Submission & MyelofibrosisBench-v1 Leaderboard","description":"Accepts citation-backed translational findings, clinical trial readouts, or errata over two-way A2A (prefix message with 'submit finding:' — zero PII, zero auth) and publishes opt-in anonymous MyelofibrosisBench-v1 model evaluations to the live leaderboard (/benchmarks/leaderboard.html & GET /api/leaderboard.json).","tags":["a2a-submission","submit-finding","MyelofibrosisBench-v1","leaderboard","open-science","benchmark"],"inputModes":null,"outputModes":null}],"skills_removed":[],"skills_changed":[],"fields_changed":[{"field":"name","before":null,"after":"Rare Disease Venture Atlas Agent"},{"field":"description","before":null,"after":"Open translational & venture diligence specialist agent anchored on Paired Myelofibrosis Flagships—Clonal JAK2 V617F+ Primary Myelofibrosis (JH2 vs JH1 allosteric selectivity, mutant CALR) and Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF, 74-80% marrow fibrosis reversal + dual transfusional & IL-6/hepcidin/ferroportin iron overload)—plus stateless hypothesis red-teaming (POST /api/stress-test), MyelofibrosisBench-v1, Hugging Face Parquet tables, non-dilutive grant stacks, 90-day validation plans, and live federated diligence across all 7,000+ orphan diseases."},{"field":"version","before":null,"after":"1.6.0"},{"field":"protocolVersion","before":null,"after":"0.3.0"},{"field":"url","before":null,"after":"https://api.rare-disease-atlas.workers.dev/a2a"},{"field":"documentationUrl","before":null,"after":"https://rare-disease-atlas.github.io/llms-full.txt"},{"field":"preferredTransport","before":null,"after":"JSONRPC"},{"field":"capabilities","before":null,"after":{"streaming":false,"pushNotifications":false,"stateTransitionHistory":false}},{"field":"provider","before":null,"after":{"organization":"Rare Disease Venture Atlas","url":"https://rare-disease-atlas.github.io"}}],"other_changed":true,"is_empty":false,"human_summary":"added 8 skills · name ∅ → Rare Disease Venture Atlas Agent · description ∅ → Open translational & venture diligence s · version ∅ → 1.6.0 · protocolVersion ∅ → 0.3.0 · url ∅ → https://api.rare-disease-atlas.workers.d · documentationUrl ∅ → https://rare-disease-atlas.github.io/llm · preferredTransport ∅ → JSONRPC · capabilities ∅ → none · provider ∅ → Rare Disease Venture Atlas"}}]}